ASCENDIS HEALTH LIMITED - Voluntary announcement: Appointment of Chief Operating Officer

Voluntary announcement: Appointment of Chief Operating Officer

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
("the Group")


VOLUNTARY ANNOUNCEMENT: APPOINTMENT OF CHIEF OPERATING OFFICER


Shareholders are advised that Dr Riyas Fadal has been appointed as chief operating officer ("COO")
of the Group with effect from 1 May 2022.

Dr Fadal (47) has extensive healthcare, health insurance and enterprise risk management
experience working with local and multinational companies. Dr Fadal joins Ascendis Health following
a seven-year tenure at Life Healthcare where he served in various non-executive and executive
leadership roles. Prior to this he worked at Medscheme, Marsh and Discovery Health.

His experience includes developing and executing turnaround strategies, acquisitions and joint
ventures, and developing and executing value generating projects. His operational expertise
includes implementing and maintenance of quality and risk management systems, contract
negotiations, supplier management and delivering efficiency projects.

Dr Fadal specialised in sports medicine and holds an MBA degree. He is the chairperson of the
Dialysis Association of SA, vice chairperson of the SA Society for Physical Rehabilitation Medicine
Society, past chairperson of the South African Neuro Rehabilitation Society. He is an appointed
member of the Council of Medical Schemes panel to review prescribed minimum benefits and was
appointed in 2020 to the World Health Organisation Parkinson Committee to develop clinical and
funding protocols. Dr Fadal is a fellow of the Global Health Leadership Forum.

In this newly created position Dr Fadal will be responsible for managing the operating companies in
the Group and will report to Cheryl-Jane Kujenga, the chief financial officer and interim chief
executive officer.

Dr Fadal’s appointment as COO provides assurance of a streamlined leadership transition and the
board and CEO look forward to working with Dr Fadal.

The Ascendis Health board of directors (the "Board") accepts responsibility for the information
contained in this announcement as it pertains to Ascendis Health. To the best of the Board's
knowledge and belief, the information contained in this announcement as it pertains to Ascendis
Health is true and nothing has been omitted which is likely to affect the importance of such
information.

3 May 2022
Bryanston

Sponsor
Questco Corporate Advisory Proprietary Limited

Date: 03-05-2022 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.